Lynx Completes One-for-Two Reverse Stock Split; Solexa Merger Still Expected to Close This Month

Mar 03, 2005

NEW YORK, March 3 (GenomeWeb News) - Lynx Therapeutics said yesterday that its board of directors has approved a one-for-two reverse split of its common stock, meaning that every two shares of common stock will be reduced to one share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Spiders and Scorpions, Oh My!

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

Keep It Secret

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Page Joins Chronic Disease Startup

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

This Week in Cell

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.

Main menu